Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
- Determine the frequency of cytopenic response in patients with T-cell large granular
lymphocytic leukemia treated with cyclosporine.
OUTLINE: This is a multicenter study.
Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of
disease progression or unacceptable toxicity.
Patients are followed every 4 months for 1 year and then every 6 months for 9 years.
PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.
Primary Purpose: Supportive Care
Frequency of cytopemic response
Maria R. Baer, MD
University of Maryland Greenebaum Cancer Center
United States: Federal Government
|Roswell Park Cancer Institute||Buffalo, New York 14263|